No evidence of fibrosis regression in HCV/HIV co-infected and HCV mono-infected participants up to 3 years after achieving SVR with DAA treatment: interim results from the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018


No evidence of fibrosis regression in HCV/HIV co-infected and HCV mono-infected participants up to 3 years after achieving SVR with DAA treatment: interim results from the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

	Reported by Jules Levin EASL 2018 April 11-15 Paris France Marion G Peters1, Minhee Kang2, Roy Matining2, Robert Murphy3, William Rosenberg4 and David L. Wyles5, on behalf of the VHICS Study Team. 1Department of Medicine, University of California San Francisco, San Francisco CA; 2Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston MA; 3Department of Medicine, Northwestern University, Chicago IL; 4UCL Institute for Liver and Digestive Health, The Royal Free London NHS Foundation Trust; 5Department of Medicine, Denver Health Medical Center, Denver CO.